AZ selects ImpactRx to check effectiveness
execute their plan of action; how well physicians perceive their efforts; and the impact of their activities on new patient treatment decisions.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.
Hires and promotions for manufacturers, regulatory and agencies
The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.